InnoCom Bio Equities

InnoCom makes investments into worthy Life Science companies, providing:

• Investment opportunities in cutting edge technologies
• Access to early commercialization for life Science innovators
• Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing
• Industry networking to access revenue at 2-3 years following pre-clinical trials
• Providing revenue and/or takeout at 7 years end of clinical trials
• Business Counsel and advice to the company management team
• Corporate Officer participation, setting up strong Systems, Procedures, and Protocols
• Board of Directors Membership, building strong Corporate Governance
• Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years
• Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years
• Enhancing the delivery of health solutions to the patients who need them